Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

Leukemia Research

Volumn 37, Issue 7, 2013, Pages 829-837

  Richardson, Paul G ^a   Mitsiades, Constantine S ^a   Laubach, Jacob P ^a   Hajek, Roman ^b   Spicka, Ivan ^c   Dimopoulos, Meletios A ^d   Moreau, Philippe ^e   Siegel, David S ^f   Jagannath, Sundar ^g   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF OSTRAVA   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY OF ATHENS   (Greece)

^e HÔTEL DIEU   (France)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; Histone deacetylase; Histone deacetylase inhibitor; Immunomodulatory drug; Multiple myeloma; Proteasome inhibitor

Indexed keywords

BELINOSTAT; BORTEZOMIB; CARFILZOMIB; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MELPHALAN; MOCETINOSTAT; PANOBINOSTAT; POMALIDOMIDE; PROTEASOME INHIBITOR; ROMIDEPSIN; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACETYLATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CARCINOGENESIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG FEVER; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TARGETING; DRUG USE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME SUBSTRATE; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MULTIPLE MYELOMA;

EID: 84878519362     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.03.006     Document Type: Review

References (107)

1. Jazirehi A.R. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anticancer Drugs 2011, 21(9):805-813.
2. Frew A.J., Johnstone R.W., Bolden J.E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett 2009, 280(2):125-133.
3. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009, 107(4):600-608.
4. Adams H., Fritzsche F.R., Dirnhofer S., Kristiansen G., Tzankov A Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. Expert Opin Ther Targets 2010, 14(6):577-584.
5. Marquard L., Poulsen C.B., Gjerdrum L.M., de Nully Brown P., Christensen I.J., Jensen P.B., et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology 2009, 54(6):688-698.
6. Wang J.C., Chen C., Dumlao T., Naik S., Chang T., Xiao Y.Y., et al. Enhanced histone deacetylase enzyme activity in primary myelofibrosis. Leuk Lymphoma 2008, 49(12):2321-2327.
7. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5(9):769-784.
8. Gibbons R.J. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 2005, 14(Spec. No. 1):R85-R92.
9. Dokmanovic M., Clarke C., Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007, 5(10):981-989.
10. Mateos M., Spencer A., Taylor K., Lonial S., de la Rubia J., Facon T., et al. Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). J Clin Oncol 2010, 28:8030. [abstract].
11. Richardson P., Weber D., Mitsiades C.S., Dimopoulos M.A., Harousseau J.-L., Hoop J., et al. A phase I study of vorinostat, lenalidomide, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: excellent tolerability and promising activity in a heavily pretreated population. Blood 2010, 116(21):813. [abstract].
12. San Miguel J., Richardson P., Sezer O., Günther A., Siegel D., Bladé J., et al. A phase 1B study of oral panobinostat plus intravenous bortezomib in relapsed or relapsed and refractory multiple myeloma: updated results at the expansion phase 2011, European Hematology Association, [abstract #0314].
13. Dimopoulos M., Siegel D., Jagannath S., Hajek R., Yoon S., Lonial S., et al. Vorinostat plus bortezomib combination therapy in patients with relapsed or relapsed and refractory multiple myeloma: VANTAGE study program update 2011, European Hematology Association, [abstract # 1009].
14. Siegel D.S., McBride L., Bilotti E., Schmidt L., Gao Z., Tufail M., et al. Vorinostat overcomes lenalidomide-dexamethasone and lenalidomide-bortezomib-dexamethasone resistance in relapsed/refractory multiple myeloma. Blood 2010, 116(21):1264. [abstract].
15. Jagannath S., Dimopoulos M.A., Lonial S. Combined proteasome and histone deacetylase inhibition: a promising synergy for patients with relapsed/refractory multiple myeloma. Leuk Res 2010, 34(9):1111-1118.
16. Glaser K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007, 74(5):659-671.
17. Yang X.J., Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol 2005, 25(8):2873-2884.
18. Khan O., La Thangue N.B. Drug insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat Clin Pract Oncol 2008, 5(12):714-726.
19. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325(5942):834-840.
20. Khan O., La Thangue N.B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012, 90(1):85-94.
21. Yang X.J., Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007, 26(37):5310-5318.
22. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26(37):5420-5432.
23. Fandy T.E., Shankar S., Ross D.D., Sausville E., Srivastava R.K. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005, 7(7):646-657.
24. Juan L.J., Shia W.J., Chen M.H., Yang W.M., Seto E., Lin Y.S., et al. Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 2000, 275(27):20436-20443.
25. Mie Lee Y., Kim S.H., Kim H.S., Jin Son M., Nakajima H., Jeong Kwon H., et al. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 2003, 300(1):241-246.
26. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Hideshima T., et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004, 101(2):540-545.
27. Arts J., Angibaud P., Marien A., Floren W., Janssens B., King P., et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer 2007, 97(10):1344-1353.
28. Sasakawa Y., Naoe Y., Sogo N., Inoue T., Sasakawa T., Matsuo M., et al. Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 2005, 69(4):603-616.
29. Sasakawa Y., Naoe Y., Inoue T., Sasakawa T., Matsuo M., Manda T., et al. Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett 2003, 195(2):161-168.
30. Lin H.Y., Chen C.S., Lin S.P., Weng J.R., Chen C.S. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006, 26(4):397-413.
31. Chen J., Fiskus W., Eaton K., Fernandez P., Wang Y., Rao R., et al. Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood 2009, 113(17):4038-4048.
32. Ellis L., Bots M., Lindemann R.K., Bolden J.E., Newbold A., Cluse L.A., et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 2009, 114(2):380-393.
33. Stamatopoulos B., Meuleman N., De Bruyn C., Delforge A., Bron D., Lagneaux L. The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces apoptosis, downregulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica 2010, 95(7):1136-1143.
34. Mitsiades N., Mitsiades C.S., Richardson P.G., McMullan C., Poulaki V., Fanourakis G., et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003, 101(10):4055-4062.
35. Campbell R.A., Sanchez E., Steinberg J., Shalitin D., Li Z.W., Chen H., et al. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Eur J Haematol 2010, 84(3):201-211.
36. Pei X.Y., Dai Y., Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004, 10(11):3839-3852.
37. Kikuchi J., Wada T., Shimizu R., Izumi T., Akutsu M., Mitsunaga K., et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood 2010, 116(3):406-417.
38. Mitsiades C., Richardson P., Grant S., Pei X.-Y., Berenson J., Richon V., et al. Vorinostat in combination with other anti-myeloma agents. Clin Lymphoma Myeloma 2009, 9:181-182. [IMW annual meeting abstract].
39. Hideshima T., Bradner J.E., Chauhan D., Anderson K.C. Intracellular protein degradation and its therapeutic implications. Clin Cancer Res 2005, 11(24 Pt 1):8530-8533.
40. Hideshima T., Bradner J.E., Wong J., Chauhan D., Richardson P., Schreiber S.L., et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005, 102(24):8567-8572.
41. Catley L., Weisberg E., Kiziltepe T., Tai Y.T., Hideshima T., Neri P., et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006, 108(10):3441-3449.
42. Nawrocki S.T., Carew J.S., Maclean K.H., Courage J.F., Huang P., Houghton J.A., et al. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008, 112:2917-2926.
43. Siegel D., Weber D.M., Mitsiades C.S., Dimopoulos M.A., Harousseau J.L., Rizvi S., et al. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: a phase I study. J Clin Oncol 2009, 27(15s, 8586).
44. Ocio E.M., Vilanova D., Atadja P., Maiso P., Crusoe E., Fernandez-Lazaro D., et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica 2010, 95(5):794-803.
45. Alexandrakis M.G., Passam F.H., Boula A., Christophoridou A., Aloizos G., Roussou P., et al. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003, 82(1):19-23.
46. Medinger M., Fischer N., Tzankov A. Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. J Oncol 2010, 2010:729725.
47. Pillai S., Kovacs M., Chellappan S. Regulation of vascular endothelial growth factor receptors by Rb and E2F1: role of acetylation. Cancer Res 2010, 70(12):4931-4940.
48. Chang S., Young B.D., Li S., Qi X., Richardson J.A., Olson E.N. Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 2006, 126(2):321-334.
49. Ha C.H., Wang W., Jhun B.S., Wong C., Hausser A., Pfizenmaier K., et al. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis. J Biol Chem 2008, 283(21):14590-14599.
50. Wang S., Li X., Parra M., Verdin E., Bassel-Duby R., Olson E.N., et al. Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci U S A 2008, 105(22):7738-7743.
51. Park J.H., Kim S.H., Choi M.C., Lee J., Oh D.Y., Im S.A., et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 2008, 368(2):318-322.
52. Deroanne C.F., Bonjean K., Servotte S., Devy L., Colige A., Clausse N., et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 2002, 21(3):427-436.
53. Chatterjee M., Jain S., Stuhmer T., Andrulis M., Ungethum U., Kuban R.J., et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007, 109(2):720-728.
54. Havasi A., Li Z., Wang Z., Martin J.L., Botla V., Ruchalski K., et al. Hsp27 inhibits Bax activation and apoptosis via a phosphatidylinositol 3-kinase-dependent mechanism. J Biol Chem 2008, 283(18):12305-12313.
55. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005, 280(29):26729-26734.
56. Fiskus W.C., Buckley K.M., Rao R., Wang Y., Joshi A., Chong D.G., et al. Synergistic activity of co-treatment with PIM1 kinase inhibitor SGI-1776 and histone deacetylase inhibitor panobinostat or heat shock protein 90 inhibitor AUY922 against human CML and myeloproliferative neoplasm (MPN) cells. Blood 2009, 114(22):2651. [abstract].
57. Mahalingam D., Swords R., Carew J.S., Nawrocki S.T., Bhalla K., Giles F.J., et al. Targeting HSP90 for cancer therapy. Br J Cancer 2009, 100(10):1523-1529.
58. Kaiser M., Lamottke B., Mieth M., Jensen M.R., Quadt C., Garcia-Echeverria C., et al. Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur J Haematol 2010, 84(4):337-344.
59. Boyault C., Zhang Y., Fritah S., Caron C., Gilquin B., Kwon S.H., et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007, 21(17):2172-2181.
60. Chesi M., Keats J., Braggio E., Bergsagel P.L., et al. The murine Vk*MYC myeloma shares defining genetic lesions with human multiple myeloma. Blood 2009, 114:1808. [abstract].
61. Chesi M., Palmer S., Bergsagel P.L. The VK*MYC mouse model of myeloma accurately reflects clinical efficacy of established and novel drugs. Blood 2009, 114:1849. [abstract].
62. Richardson P.G., Mitsiades C.S., Colson K., Reilly E., McBride L., Chiao J., et al. Final results of a phase I trial of oral vorinostat (suberoylanilide hydroxamic acid SAHA) in patients with advanced multiple myeloma. Blood 2007, 110(11):1179. [abstract].
63. Schmitt S., Ho A.D., Goldschmidt H. The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide. Onkologie 2010, 33(4):183-186.
64. Wolf J.L., Siegel D., Matous J., Lonial S., Goldschmidt H., Schmitt S., et al. A phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma. Blood 2008, 112(11):2774. [abstract].
65. Niesvizky R., Ely S., Mark T., Aggarwal S., Gabrilove J.L., Wright J.J., et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011, 117(2):336-342.
66. Richardson P., Mitsiades C., Colson K., Reilly E., McBride L., Chiao J., et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008, 49(3):502-507.
67. Wolf J.L., Siegel D., Goldschmidt H., Hazell K., Bourquelot P.M., Bengoudifa B.R., et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 2012, 53(9):1820-1823.
68. Alsayed Y., Nair B., Kauffman M., Petty N., Waheed S., Van Rhee F., et al. Carfilzomib (CFZ) in combination with DEX and other agents (Dox, Thal, DDP, vorinostat) for far advanced and refractory multiple myeloma (FARMM). J Clin Oncol 2010, 28(15 Suppl):e18504. [abstract].
69. Alsina M., Lonial S., Weber D.M., Coutre S.E., Kang B.P., Glynos R., et al. PANORAMA 2: a phase II study of panobinostat (LBH589) in combination with bortezomib (BTZ) and dexamethasone (DEX) in patients with relapsed and BTZ-refractory multiple myeloma (MM). J Clin Oncol 2010, 28:TPS308. [abstract].
70. Harrison S.J., Quach H., Yuen K., Strayer A., Copeman M.C., Peinert S., et al. High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial. Blood 2008, 112(11):3698. [abstract].
71. Siegel D.S., Dimopoulos M.A., Yoon S.S., Laubach J.P., Kaufman J.L., Goldschmidt H., et al. Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. Blood 2011, [Abstract 480].
72. Sullivan D., Singhal S., Schuster M., Berenson J., Gimsing P., Wislöff F., et al. A phase II study of PXD101 in advanced multiple myeloma. Blood 2006, 108. [Abstract 3583].
73. A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine. NLM Identifier: . [accessed 19.12.11]. http://clinicaltrials.gov/ct2/show/NCT00431340.
74. San Miguel J., Sezer O., Siegel D., Guenther A., Blade J., Prosser I., et al. A phase IB dose-escalation study of oral panobinostat (LBH589) and IV bortezomib in patients with relapsed or relapsed and refractory multiple myeloma. Haematologica 2010, 95(Suppl 2):155. [abstract 0384].
75. Richardson P.G., Alsina M., Weber D.M., Coutre S.E., Lonial S., Gasparetto C., et al. Phase II study of the pan-deacetylase inhibitor panobinostat in combination with bortezomib and dexamethasone in Relapsed and bortezomib-refractory multiple myeloma (PANORAMA 2). ASH annual meeting abstracts 2011, 814.
76. San-Miguel J.F., de Moraes Hungria V.T., Yoon S.-S., Wiktor-Jedrzejczak W., Elghandour A., Siritanaratkul N., et al. Update on a phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma: PANORAMA 1. ASH annual meeting abstracts 2011, 3976.
77. Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine. NLM Identifier: . [accessed 23.02.12]. http://clinicaltrials.gov/ct2/show/NCT01323751.
78. Offidani M., Polloni C., Cavallo F., Liberati A.M., Ballanti S., Pulini S., et al. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma 2012, 10.3109/10428194.2012.664844.
79. Harrison S.J., Quach H., Link E., Seymour J.F., Ritchie D.S., Ruell S., et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 2011, 118(24):6274-6283.
80. Vorinostat, Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens (RZD). NLM Identifier: . [accessed 24.02.12]. http://clinicaltrials.gov/ct2/show/NCT01502085.
81. Dimopoulos M.A., Jagannath S., Yoon S.S., Siegel D.S., Lonial S., Hajek R., et al. Vantage 088: vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: results of a global, randomized phase 3 trial. Blood 2011, [Abstract 811].
82. Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Versus Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine. NLM Identifier: . [accessed 08.03.12]. http://clinicaltrials.gov/ct2/show/NCT01080391.
83. Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine. NLM Identifier: . [accessed 08.03.12]. http://clinicaltrials.gov/ct2/show/NCT00511238.
84. Siegel D.S., Dimopoulos M.A., Yoon S.S., Laubach J.P., Kaufman J.L., Goldschmidt H., et al. VANTAGE 095:Final results from a global, single-arm, phase 2b trial of vorinostat in combination with bortezomib in salvage multiple myeloma patients. Haematologica 2012, 97(s1):119. [abstract no. 0294].
85. Dimopoulos M.A., Jagannath S., Yoon S.S., Siegel D.S., Lonial S., Qi J., et al. VANTAGE 088: Final results from the global phase 3 trial of the multihistone deacetylase inhibitor vorinostat in combination with bortezomib in relapsed/refractory multiple myeloma. Haematologica 2012, 93(s1):113. [abstract no. 0281].
86. Berenson J.R., Yellin O., Boccia R.V., Nassir Y., Rothstein S., Swift R., et al. A phase I study of oral melphalan combined with LBH589 for patients with relapsed or refractory multiple myeloma (MM). Blood 2009, 114(22):1855. [abstract].
87. Voorhees P.M., Gasparetto C., Osman K., Richards K., Ferraro M., Garcia R., et al. Results of a phase I study of vorinostat in combination with pegylated liposomal doxorubicin and bortezomib in patients with relapsed/refractory multiple myeloma. Blood 2010, 116(21):815. [abstract].
88. Palumbo A., Gay F. How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematol Am Soc Hematol Educ Program 2009, 566-577.
89. Richardson P.G., Laubach J., Mitsiades C., Schlossman R.L., Doss D., Colson K., et al. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park) 2010, 24(3 Suppl 2):22-29.
90. Itoh Y., Suzuki T., Miyata N. Isoform-selective histone deacetylase inhibitors. Curr Pharm Des 2008, 14(6):529-544.
91. Mack G.S. To selectivity and beyond. Nat Biotechnol 2010, 28(12):1259-1266.
92. Santo L., Hideshima T., Kung A.L., Tseng J.C., Tamang D., Yang M., et al. Preclinical activity, pharmacodynamic and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012, 119(11):2579-2589.
93. Bantscheff M., Hopf C., Savitski M.M., Dittmann A., Grandi P., Michon A.M., et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011, 29(3):255-265.
94. Dell'Aversana C., Lepore I., Altucci L. HDAC modulation and cell death in the clinic. Exp Cell Res 2012, 318(11):1229-1244.
95. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23(17):3923-3931.
96. Kelly W.K., Richon V.M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9(10 Pt 1):3578-3588.
97. Maiso P., Carvajal-Vergara X., Ocio E.M., Lopez-Perez R., Mateo G., Gutierrez N., et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006, 66(11):5781-5789.
98. Morita S., Oizumi S., Minami H., Kitagawa K., Komatsu Y., Fujiwara Y., et al. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors. Invest New Drugs 2012, 30(5):1950-1957.
99. Plumb J.A., Finn P.W., Williams R.J., Bandara M.J., Romero M.R., Watkins C.J., et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003, 2(8):721-728.
100. Steele N.L., Plumb J.A., Vidal L., Tjornelund J., Knoblauch P., Buhl-Jensen P., et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother Pharmacol 2011, 67(6):1273-1279.
101. Steele N.L., Plumb J.A., Vidal L., Tjornelund J., Knoblauch P., Rasmussen A., et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008, 14(3):804-810.
102. Hu E., Dul E., Sung C.M., Chen Z., Kirkpatrick R., Zhang G.F., et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003, 307(2):720-728.
103. Gore L., Rothenberg M.L., O'Bryant C.L., Schultz M.K., Sandler A.B., Coffin D., et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008, 14(14):4517-4525.
104. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005, 23(17):3912-3922.
105. Fournel M., Bonfils C., Hou Y., Yan P.T., Trachy-Bourget M.C., Kalita A., et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008, 7(4):759-768.
106. Garcia-Manero G., Assouline S., Cortes J., Estrov Z., Kantarjian H., Yang H., et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008, 112(4):981-989.
107. Klimek V.M., Fircanis S., Maslak P., Guernah I., Baum M., Wu N., et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008, 14(3):826-832.